Sordarin antifungal agents
- 25 February 2001
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 11 (2) , 283-294
- https://doi.org/10.1517/13543776.11.2.283
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Pharmacokinetics-Pharmacodynamics of a Sordarin Derivative (GM 237354) in a Murine Model of Lethal CandidiasisAntimicrobial Agents and Chemotherapy, 2000
- Efficacies of Sordarin Derivatives GM193663, GM211676, and GM237354 in a Murine Model of Systemic CoccidioidomycosisAntimicrobial Agents and Chemotherapy, 2000
- In Vitro Pharmacodynamic Parameters of Sordarin Derivatives in Comparison with Those of Marketed Compounds against Pneumocystis carinii Isolated from RatsAntimicrobial Agents and Chemotherapy, 2000
- Synthesis of a monocyclic core of the antifungal sordarinsTetrahedron Letters, 1998
- Ribosomal P-protein Stalk Function Is Targeted by Sordarin AntifungalsPublished by Elsevier ,1998
- Elongation Factor 2 as a Novel Target for Selective Inhibition of Fungal Protein SynthesisJournal of Biological Chemistry, 1998
- CH57404, an Antifungal Agent Possessing the Rare Sodaricin Skeleton and a Tricyclic Sugar Moiety.The Journal of Antibiotics, 1995
- Translation elongation factor 3: a fungus‐specific translation factor?Molecular Microbiology, 1993
- Elongation factor 3 (EF-3) from Candida albicans shows both structural and functional similarity to EF-3 from Saccharomyces cerevisiaeMolecular Microbiology, 1992
- Isolierung und Abbau von Sordarin. 1. Mitteilung über SordarinHelvetica Chimica Acta, 1971